Loading...

To get the team

What he specialises in

Konstantin has more than 15 years of experience in law, for over 12 of which he has been providing legal assistance to pharmaceutical companies in Russia and the CIS. He specialises in transactions with assets in the area of pharmaceuticals, solving complex regulatory issues, including those connected with intellectual property of pharmaceutical companies, localisation of manufacturing in Russia, and contractual regulation of relationships between those involved in the circulation of medicines and medical devices in Russia.

Konstantin has vast experience of representing clients in negotiations, within the framework of complaint proceedings and in litigation, including in disputes with supervisory authorities.

His key achievements

Among Konstantin’s major projects are:
  • provided successful legal support for a major transaction on the market of Russia and the CIS to dispose of a portfolio of medicines, and other transactions with assets in Russia and the CIS;
  • provided legal support for the localisation of the manufacturing of medicines and medical devices from production sites in the EU to the ones in Russia;
  • represented clients in disputes with supervisory authorities and also within the framework of disputes in the field of intellectual property;
  • prepared legal opinions on various issues related to launching original and generic drugs on the market, and registering biologically active supplements and medical devices;
  • developed and implemented commercial and credit policies of a pharmaceutical company in Russia and the CIS.

What they say

Pepeliaev Group's team exhibits “excellent value for money and a result-oriented approach” (Legal 500).

Publications

15.12.2025
Pepeliaev Group has strengthened its position in the “PRO Bankruptcy Leaders” ranking of law firms
Read more
11.12.2025
Sergey Pepeliaev joins the working group of the Agency for Strategic Initiatives
Read more
05.12.2025
Pepeliaev Group has expanded its presence in the Pravo-300 ranking in 2025
Read more